Similarly, in prostate cancer the positive determination androgen receptor splice variant 7 (AR-V7) in CTCs showed a better response to taxanes on display, superior overall survival, and resistance to enzalutamide and abiraterone [18]. Here, AR is linked to prostate cancer.